Abstract: The Clinical Biomanufacturing Facility (CBF) at the University of Oxford (UK) produced the first clinical batches of the ChAdOx1 nCoV-19 vaccine against SARS-coV-2 in April 2020. This vaccine is now in phase III clinical trials across the globe, and in scaled up manufacture to produce millions of doses in the hope that it will provide effective protection against COVID-19. I will present the efforts that underpinned this highly rapid development of a vaccine against a provisionally unknown pathogen, the lessons that we have learnt, as well as the results generated from our early phase trials.

Biography: Catherine Green heads the Clinical Biomanufacturing Facility at the University of Oxford, she is an Associate Professor at the Wellcome Centre for Human Genetics, and a Senior Research Fellow at Exeter College Oxford. Her team at the CBF manufacture biologics at GMP for first in man and early phase clinical trials. Recently the CBF has been manufacturing simian Adenovirus vectored vaccines for a variety of pathogens with significant global disease burden, including Malaria, Zika, Rabies, Chikungunya. 2020 was a challenging year as we developed, manufactured, released and distributed into global clinical trials the ChAdOx1 nCoV-19 vaccine against COVID-19 which was recently acquired by AstraZeneca.